Thank you for the question.
To be clear, that $2.5 billion, which was originally in our statutory forecast, has migrated over to be on a voted basis, and the total amount that we're looking at is about $9.2 billion.
Of that $9.2 billion, about $8 billion is for bilateral purchase agreements pertaining to the vaccines for COVID-19, $1 billion is for strategic international partnerships, and then about $200 million is for treatments and therapeutics, such as the drug remdesivir and so forth.
That $2.5 billion effectively completes the $9.2 billion envelope that exists in the system.